Cite
Wenk AS, Becker U, Klawitter S, et al. Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll). Value Health. 2014;17(7):A522doi: 10.1016/j.jval.2014.08.1636.
Wenk, A. S., Becker, U., Klawitter, S., Wiesner, C., & Bernhardt, A. (2014). Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A522. https://doi.org/10.1016/j.jval.2014.08.1636
Wenk, Andres S, et al. "Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A522. doi: https://doi.org/10.1016/j.jval.2014.08.1636
Wenk AS, Becker U, Klawitter S, Wiesner C, Bernhardt A. Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll). Value Health. 2014 Nov;17(7):A522. doi: 10.1016/j.jval.2014.08.1636. Epub 2014 Oct 26. PMID: 27201638.
Copy
Download .nbib
